Medicines & Healthcare products Regulatory Agency

NIBSC Confidence in Biological Medicines

WHO International Standard
First International Standard for Anti-Rift Valley fever virus antibodies for binding assays (human plasma)
NIBSC code: 22/104_BA
Instructions for use
(Version 1.0, Dated 19/05/2023)

§

1. INTENDED USE

The First WHO International Standard for anti-Rift Valley fever antibodies for binding assays is the freeze-dried equivalent of 0.25 mL of pooled plasma obtained from seven individuals recovered from Rift Valley fever (RVF). The preparation has been evaluated in a WHO International collaborative study (1). The intended use of the International Standard is for the calibration and harmonisation of serological assays detecting binding immunoglobulin G to the RVFV glycoprotein (GnGc). The preparation has been solvent detergent treated to minimise the risk of the presence of enveloped viruses (2).

2. CAUTION

This preparation is not for administration to humans or animals in the human food chain.

The preparation contains material of human origin, and either the final product or the source materials, from which it is derived, have been tested and found negative for HBsAg, anti-HIV and HCV RNA. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

3. UNITAGE

The assigned potency of the WHO International Standard for anti-RVFV antibodies is 250 IU/ampoule for binding immunoglobulin G to the glycoprotein (GnGc). The potency of the preparation against different components of the glycoprotein (Gn, Gc or combined) may be different and therefore we recommend specifying the antigen used in the binding assay. These values have been arbitrarily chosen and do not reflect the proportion of the antibody activities in the preparation. After reconstitution of the lyophilised cake in 0.25 mL of distilled water or other matrix, the final concentration will be 1000 IU/mL for anti-glycoprotein IgG.

International Units are arbitrary assigned to a WHO International Standard to express the biological activity of the standard, and as such there is no conversion factor between IU and mass (e.g. ng of antibody).

4. CONTENTS

Country of origin of biological material: Uganda.
Each ampoule contains the freeze-dried equivalent of 0.25 mL of pooled human plasma.

5. STORAGE

Ampoules should be stored at -20°C or below until use.
Please note because of the inherent stability of lyophilized material, NIBSC may ship these materials at ambient temperature.

6. DIRECTIONS FOR OPENING

DIN ampoules have an 'easy-open' coloured stress point, where the narrow ampoule stem joins the wider ampoule body. Various types of ampoule breaker are available commercially. To open the ampoule, tap the ampoule gently to collect material at the bottom (labelled) end and follow manufactures instructions provided with the ampoule breaker.

7. USE OF MATERIAL

No attempt should be made to weigh out any portion of the freeze-dried material prior to reconstitution

The contents of each ampoule should be reconstituted in 0.25mL distilled water. Following addition of the distilled water, the material must be allowed to become fully dissolved before use. This may take 30 minutes or more.

8. STABILITY

Reference materials are held at NIBSC within assured, temperature-controlled storage facilities. Reference Materials should be stored on receipt as indicated on the label.

NIBSC follows the policy of WHO with respect to its reference materials.

9. REFERENCES

(1) Bentley et al. Establishment of the First WHO International Standard for anti-Rift Valley fever virus antibody. 2023 WHO Expert Committee on Biological Standardization. WHO/BS/2023.2450
(2) Dichtelmuller, H.O., et al., Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies. Transfusion, 2009. 49(9): p. 1931-43

10. ACKNOWLEDGEMENTS

We would like to wholeheartedly thank the anonymous donors of the plasma samples for their consent which has allowed the preparation of this Standard. We would like to express our gratitude to the team at Integrum Scientific (USA) in partnership with the Uganda Virus Research Institute (UVRI) for the collection and testing of the plasma samples. We gratefully acknowledge the important contributions of the collaborative study (1) participants for evaluating the standard. We would also like to thank MHRA Manufacturing and Logistics teams for the formulation and distribution of materials.
The project has been funded by the Coalition for Epidemic Preparedness Innovations.

11. FURTHER INFORMATION

Further information can be obtained as follows;
This material: enquiries@nibsc.org
WHO Biological Standards:
http://www.who.int/biologicals/en/
JCTLM Higher order reference materials:
http://www.bipm.org/en/committees/jc/jctlm/
Derivation of International Units:
http://www.nibsc.org/standardisation/international_standards.aspx
Ordering standards from NIBSC:
http://www.nibsc.org/products/ordering.aspx
NIBSC Terms & Conditions:
http://www.nibsc.org/terms_and_conditions.aspx

National Institute for Biological Standards and Control,
Potters Bar, Hertfordshire, EN6 3QG. T +44 (0)1707 641000, nibsc.org
WHO International Laboratory for Biological Standards,
UK Official Medicines Control Laboratory

World Health Organization

12. CUSTOMER FEEDBACK

Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

13. CITATION

In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

14. MATERIAL SAFETY SHEET

Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

Physical and Chemical properties	
Physical appearance: freeze-dried	Corrosive: No
Stable: Yes	Oxidising: No
Hygroscopic: No	Irritant: No
Flammable: No	Handling: See caution, Section 2
Other (specify): human origin	
Toxicological properties	
Effects of inhalation:	Not established, avoid inhalation
Effects of ingestion:	Not established, avoid ingestion
Effects of skin absorption:	Not established, avoid contact with skin
Suggested First Aid	
Inhalation:	Seek medical advice
Ingestion:	Seek medical advice
Contact with eyes:	Wash with copious amounts of water. Seek medical advice
Contact with skin:	Wash thoroughly with water.
Action on Spillage and Method of Disposal	
Spillage of ampoule contents should be taken up with absorbent material wetted with an appropriate disinfectant. Rinse area with an appropriate disinfectant followed by water. Absorbent materials used to treat spillage should be treated as biological waste.	

15. LIABILITY AND LOSS

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.

Unless expressly stated otherwise by NIBSC, NIBSC's Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by the Recipient) ("Conditions") apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of the Conditions.

16. INFORMATION FOR CUSTOMS USE ONLY

Country of origin for customs purposes*: United Kingdom * Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying.
Net weight: 0.25
Toxicity Statement: Non-toxic
Veterinary certificate or other statement if applicable. **Attached:** No

17. CERTIFICATE OF ANALYSIS

NIBSC does not provide a Certificate of Analysis for WHO Biological Reference Materials because they are internationally recognised primary reference materials fully described in the instructions for use. The reference materials are established according to the WHO Recommendations for the preparation, characterization and establishment of international and other biological reference standards http://www.who.int/bloodproducts/publications/TRS932Annex2_Inter_biolefstandardsrev2004.pdf (revised 2004). They are officially endorsed by the WHO Expert Committee on Biological Standardization (ECBS) based on the report of the international collaborative study which established their suitability for the intended use.